The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InReflecting strong momentum within the biotechnology sector, Alkermes shares reached new heights following financial results that outpaced expectations. The company's Q1 2026 revenues surged by 28.2% to $392.9 million, propelling the stock to a new 52-week high of $43.38. Additionally, the firm announced it will present pivotal new data on its alixorexton and LUMRYZ programs at the upcoming SLEEP 2026 meeting.
This robust performance comes amid intensifying competition in the sleep medicine and neurological disorder markets, where peer Jazz Pharmaceuticals recently reported an 18% growth in Xywav sales per its latest earnings release. Compared to the fourth quarter of 2025, Alkermes maintained steady growth in VIVITROL sales, bolstering its market capitalization to approximately $7.21 billion per market data.
Regarding market action, ALKS shares remained near their peak at the close of June 4, 2026, with investors watching the $40 support level to sustain the current bullish trend. Looking ahead at the economic calendar, market participants are monitoring upcoming global inflation data next week for broader sector impact, alongside the company's scheduled clinical presentations at the SLEEP conference.